ATE478062T1 - Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid - Google Patents
Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloidInfo
- Publication number
- ATE478062T1 ATE478062T1 AT04750543T AT04750543T ATE478062T1 AT E478062 T1 ATE478062 T1 AT E478062T1 AT 04750543 T AT04750543 T AT 04750543T AT 04750543 T AT04750543 T AT 04750543T AT E478062 T1 ATE478062 T1 AT E478062T1
- Authority
- AT
- Austria
- Prior art keywords
- amyloid
- vivo
- imaging
- compositions
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
- 238000003384 imaging method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 101800001718 Amyloid-beta protein Proteins 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/431,202 US20040223912A1 (en) | 2003-05-07 | 2003-05-07 | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
| US10/747,715 US20040223909A1 (en) | 2003-05-07 | 2003-12-26 | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
| PCT/US2004/012559 WO2004100998A2 (en) | 2003-05-07 | 2004-04-23 | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE478062T1 true ATE478062T1 (de) | 2010-09-15 |
Family
ID=33416408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04750543T ATE478062T1 (de) | 2003-05-07 | 2004-04-23 | Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20040223912A1 (de) |
| JP (1) | JP4831421B2 (de) |
| AT (1) | ATE478062T1 (de) |
| DE (1) | DE602004028731D1 (de) |
| ES (1) | ES2348870T3 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| WO2007027963A2 (en) * | 2005-08-30 | 2007-03-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of screening bifunctional molecules for modulated pharmacokinetic properties |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| NZ568012A (en) | 2005-12-12 | 2012-07-27 | Ac Immune Sa | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| JP2009524826A (ja) | 2006-01-26 | 2009-07-02 | ザ ユニヴァーシティー オブ テキサス | 撮像のための方法及び装置 |
| RU2498999C2 (ru) | 2006-07-14 | 2013-11-20 | Ац Иммуне Са | Гуманизированное антитело к амилоиду бета |
| KR100858357B1 (ko) | 2006-10-02 | 2008-09-11 | (주) 디지탈바이오텍 | 벤조퓨란계 유도체 화합물을 유효성분으로 함유하는인지기능 장애의 예방 및 치료용 조성물 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| ES2569660T3 (es) | 2007-06-08 | 2016-05-12 | Mannkind Corporation | Inhibidores de la IRE-1alfa |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| PL2238166T3 (pl) | 2007-10-05 | 2014-07-31 | Genentech Inc | Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu |
| GB0722650D0 (en) * | 2007-11-19 | 2007-12-27 | Ge Healthcare Ltd | Novel imaging method |
| US20090162280A1 (en) * | 2007-12-20 | 2009-06-25 | General Electric Company | Detecting soluble a-beta |
| WO2009086539A2 (en) * | 2007-12-28 | 2009-07-09 | Elan Pharmaceuticals, Inc. | Treatment and prophylaxis of amyloidosis |
| US8193363B2 (en) * | 2008-08-29 | 2012-06-05 | Astrazeneca Ab | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits |
| US9801865B2 (en) * | 2008-09-24 | 2017-10-31 | The United States Of America As Represented By The Department Of Veteran Affairs | Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation |
| US8512677B2 (en) * | 2009-04-27 | 2013-08-20 | Case Western Reserve University | Pyro-glutamate Aβ targeting agents |
| US9198985B2 (en) | 2009-05-22 | 2015-12-01 | Vanderbuilt University | Bimodal star polymer architectures as fluorescent and MRI imaging reagents |
| WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
| US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| WO2018150276A2 (en) | 2017-02-16 | 2018-08-23 | Universidad San Sebastian | The combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological conditions |
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
| CN111072605B (zh) * | 2019-12-17 | 2021-11-02 | 赣南医学院 | 一种氟烷基取代的苯并呋喃衍生物或吲哚衍生物的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560534A (en) * | 1983-11-02 | 1985-12-24 | Miles Laboratories, Inc. | Polymer catalyst transducers |
| US5811310A (en) * | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| US5231000A (en) * | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
| US6287793B1 (en) * | 1988-08-19 | 2001-09-11 | Elan Pharmaceuticals, Inc. | Diagnostic methods for alzheimer's disease |
| US5434050A (en) * | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
| US5272055A (en) * | 1991-12-24 | 1993-12-21 | The University Of Kentucky Research Foundation | Detection of Alzheimer's disease and other diseases using a photoaffinity labeling method |
| US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| US5837672A (en) * | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
| EP0683234B2 (de) * | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
| CN1136327A (zh) * | 1993-09-28 | 1996-11-20 | 综合医院公司 | 用反义寡核苷酸调节神经生长并使β/A4淀粉样肽诱导的形态逆转 |
| US6168776B1 (en) * | 1994-07-19 | 2001-01-02 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| US6417178B1 (en) * | 1994-07-19 | 2002-07-09 | University Of Pittsburgh | Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits |
| US6703407B1 (en) * | 1994-09-20 | 2004-03-09 | Eli Lilly And Company | Benzofuran compounds, compositions, and methods |
| US6114133A (en) * | 1994-11-14 | 2000-09-05 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) |
| US5520904A (en) * | 1995-01-27 | 1996-05-28 | Mallinckrodt Medical, Inc. | Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging |
| US5523309A (en) * | 1995-03-10 | 1996-06-04 | Eli Lilly And Company | Benzofuran pharmaceutical compounds |
| EP0866805A1 (de) * | 1995-12-12 | 1998-09-30 | Karolinska Innovations AB | Peptide, das die KLVFF Sequenz von beta-Amyloid bindet |
| US6054114A (en) * | 1996-05-08 | 2000-04-25 | Massachusetts Institute Of Technology | Organometallic ligands for the localization and quantification of amyloid in vivo and in vitro |
| EP1105163A4 (de) * | 1998-08-20 | 2003-05-02 | Univ California | Verfahren zur markierung amyloider plaques und neurofibrillisches gewirrs |
| WO2001046179A1 (en) * | 1999-12-20 | 2001-06-28 | Eli Lilly And Company | Piperidine derivatives and their use as serotonin receptor antagonists |
| WO2001087354A2 (en) * | 2000-05-17 | 2001-11-22 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
| RU2324686C2 (ru) * | 2000-08-24 | 2008-05-20 | Юнивесити Оф Питсбэг | ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА |
| AUPR283801A0 (en) * | 2001-02-01 | 2001-03-01 | Australian National University, The | Chemical compounds and methods |
| EP2298361A3 (de) * | 2001-04-27 | 2011-05-04 | The General Hospital Corporation | Okulare Diagnose der Alzheimer-Krankheit |
-
2003
- 2003-05-07 US US10/431,202 patent/US20040223912A1/en not_active Abandoned
- 2003-12-26 US US10/747,715 patent/US20040223909A1/en not_active Abandoned
-
2004
- 2004-04-23 DE DE602004028731T patent/DE602004028731D1/de not_active Expired - Lifetime
- 2004-04-23 JP JP2006532458A patent/JP4831421B2/ja not_active Expired - Fee Related
- 2004-04-23 ES ES04750543T patent/ES2348870T3/es not_active Expired - Lifetime
- 2004-04-23 AT AT04750543T patent/ATE478062T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP4831421B2 (ja) | 2011-12-07 |
| US20040223912A1 (en) | 2004-11-11 |
| US20040223909A1 (en) | 2004-11-11 |
| ES2348870T3 (es) | 2010-12-16 |
| DE602004028731D1 (de) | 2010-09-30 |
| JP2006528684A (ja) | 2006-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004028731D1 (de) | Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid | |
| WO2004100998A3 (en) | Compositions and methods for non-invasive imaging of soluble beta-amyloid | |
| DE60126592D1 (de) | Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs | |
| ATE528410T1 (de) | Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration | |
| ATE461449T1 (de) | Verfahren zum nachweis von medizinisch relevanten zuständen in gelösten lbc-proben | |
| ATE443260T1 (de) | Kontrastmittel und verfahren zum imaging von naaldase oder psma | |
| ATE349446T1 (de) | Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel | |
| DE60233485D1 (de) | Verfahren zur diagnose, behandlung und prävention von knochenverlust | |
| EP1505990A4 (de) | Verfahren zur behandlung von hepatitis | |
| CY1105322T1 (el) | Μεθοδοι και συνθεσεις για την ανιχνευση παθολογικων συμβαντων | |
| ATE376428T1 (de) | Metallkomplexverbindungen | |
| JP5927634B2 (ja) | 多孔質歯科ハイドロキシアパタイトを検出するためのキットおよび方法 | |
| IL175667A (en) | Imaging agent which comrises a synthetic caspase-3 inhibitor labeled with an imaging moiety, a radiopharmaceutical composition comprising the same, a kit for the preparation of said composition and a method of diagnosis based thereon | |
| DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
| ATE522230T1 (de) | Biphenyle als bilderzeugungsmittel bei der alzheimerschen krankheit | |
| ATE504580T1 (de) | Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit | |
| ATE310736T1 (de) | Verbindungen zur bilddarstellung der alzheimer- krankenheit | |
| DE60221115D1 (de) | Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose | |
| ATE495271T1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
| EP1496743A4 (de) | Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs | |
| ATE534037T1 (de) | Verwendung des proteins asc als marker für brustkrebs | |
| DE60324820D1 (de) | Verfahren zum testen des oxidiertes-ldl-beta-2-glycoprotein-i-komplexes in vivo | |
| NZ590993A (en) | Dual specificity phosphatase 1 protein (DUSP1) for diagnosis and prognosis of skin cancer | |
| ATE529750T1 (de) | Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target | |
| DE602006016106D1 (de) | Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |